By binding to Bcl-2 and blocking its actions, it has proven efficacious for the treatment of other cancers where the Bcl-2 protein is highly expressed, such as chronic lymphocytic leukemia. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.